CHINA WUYI MOUNTAIN, LTD.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
|
|
Six months ended
February 28, 2019
|
|
Six months ended
February 28,
2018
|
|
|
|
|
|
OPERATING ACTIVITIES
|
|
|
|
|
|
|
|
|
Net loss for the period
|
|
$
|
(30,900
|
)
|
|
$
|
(7,503
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Increase (decrease) in accounts payables
|
|
|
3,372
|
|
|
|
(798
|
)
|
Other receivable
|
|
|
(20,000
|
)
|
|
|
-
|
|
Increase (decrease) in other liability
|
|
|
-
|
|
|
|
(2,500
|
)
|
|
|
|
|
|
|
|
|
|
NET CASH USED IN OPERATING ACTIVITIES
|
|
|
(47,528
|
)
|
|
|
(10,801
|
)
|
|
|
|
|
|
|
|
|
|
CASH FLOW FROM INVESTING ACTIVITIES
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
CASH FLOW FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
Proceeds on sale of common stock
|
|
|
-
|
|
|
|
-
|
|
Related party advances
|
|
|
7,749
|
|
|
|
12,500
|
|
|
|
|
|
|
|
|
|
|
NET CASH PROVIDED BY FINANCING ACTIVITIES
|
|
|
7,749
|
|
|
|
12,500
|
|
|
|
|
|
|
|
|
|
|
NET INCREASE (DECREASE) IN CASH
|
|
|
(39,779
|
)
|
|
|
1,699
|
|
|
|
|
|
|
|
|
|
|
CASH, BEGINNING
|
|
|
40,885
|
|
|
|
4,211
|
|
|
|
|
|
|
|
|
|
|
CASH, ENDING
|
|
$
|
1,106
|
|
|
$
|
5,910
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL CASH FLOW INFORMATION AND NONCASH FINANCING ACTIVITIES;
|
|
|
|
|
|
|
|
|
Cash paid during the period for:
|
|
|
|
|
|
|
|
|
Interest
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
Income taxes
|
|
$
|
-
|
|
|
$
|
-
|
|
Related party debt forgiveness
|
|
$
|
-
|
|
|
$
|
5,501
|
|
|
|
|
|
|
|
|
|
|
The accompanying
notes are an integral part of these condensed financial statements.
CHINA WUYI MOUNTAIN, LTD
NOTES TO CONDENSED FINANCIAL STATEMENTS
February
28, 2019 (unaudited)
|
NOTE 1 – NATURE OF OPERATIONS AND
BASIS OF PRESENTATION
KOKOS GROUP INC. was incorporated in the State of Nevada as a for-profit
Company on July 26, 2016 and established a fiscal year end of August 31. The Company is organized to bottle, market, distribute
and sell our own brand of coconut water, presently called “Koos Coconut Water”. On November 10, 2017 the Board of directors
and the majority of its shareholders of Kokos Group Inc., amended the Company’s current Certificate of Incorporation in conformity
with the applicable laws of the State of Nevada to change the name of the Company from Kokos Group Inc. to China Wu Yi Mountain
Ltd. On May 24, 2018 FINRA approved the Company’s corporate action changing the Company’s name and trading symbol effective
May 25, 2018.
On October 19, 2017 Mr. Lei Wang became
its Chief Executive Officer, Chief Financial Officer and sole Director and Mr. Richard Rappaprt was appointed Secretary. In addition,
Mr. Baterina and Messrs. Flemming H.H. Hansen and Arthur T. Claravall submitted his resignations from all executive officer positions
with the Company, including Chief Executive Officer and President effective October 19, 2017, and each submitted their resignation
as a member of the Board. On January 18, 2018, Richard Rappaport submitted his resignation as Secretary of Kokos Group Inc. (the
"Company"), effective immediately. On the same day, Ying Zhang was appointed Secretary, effective immediately.
Going concern
To date the Company has generated no revenues
from its business operations and has incurred operating losses since inception of $143,223. As at February 28, 2019 the Company
has working capital deficit of $18,132. The Company requires additional funding to meet its ongoing obligations and to fund anticipated
operating losses. The ability of the Company to continue as a going concern is dependent on raising capital to fund its initial
business plan and ultimately to attain profitable operations. Accordingly, these factors raise substantial doubt as to the Company’s
ability to continue as a going concern. The Company intends to continue to fund its business by way of private placements and advances
from related parties as may be required. As of February 28, 2019, the Company has issued 800,000,000 founders shares at $0.0000125
per share for net proceeds of $10,000 to the Company and private placements of 25,600,000 common shares at $0.000375 per share
for net proceeds of $9,600.
On May 2, 2018, the Company entered into a subscription agreement
with a China-based company, Grand Biotechnology Group Liaoning, (the authorized signor for Grand Biotechnology is a 4.9% shareholder
of the Company), for the issuance of an aggregate of 20,000,000 shares of restricted common stock at $0.0075 per share for an aggregate
purchase price of U.S.$150,000. On May 15, 2018 the Company had received $100,000.
These financial statements do not include
any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities
that might result from this uncertainty.
NOTE 2 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited financial statements
have been prepared in accordance with generally accepted accounting principles for financial information and with the instructions
to Form 10-Q. They do not include all information and footnotes required by United States generally accepted accounting principles
for complete financial statements. However, except as disclosed herein, there has been no material changes in the information disclosed
in the notes to the financial statements for the fiscal year ended August 31, 2018 included in the Company’s 10-K filed with
the Securities and Exchange Commission on January 18, 2019 and amendment on February 27, 2019 . The unaudited financial statements
should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of Management, all adjustments
considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results
for the six months ended February 28, 2019 are not necessarily indicative of the results that may be expected for the year ending
August 31, 2019.
Segmented Reporting
FSAB ASC 280, “Disclosure about Segments of an Enterprise
and Related Information”, changed the way public companies report information about segments of their business in their quarterly
reports issued to shareholders. It also requires entity-wide disclosures about the products and services the entity provides, the
material countries in which it holds assets and reports revenues and its major customers.
CHINA WUYI MOUNTAIN, LTD
NOTES TO CONDENSED FINANCIAL STATEMENTS
February
28, 2019 (unaudited)
|
NOTE 2 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (continued)
Comprehensive Loss
“Reporting Comprehensive Income,” establishes standards
for the reporting and display of comprehensive loss and its components in the financial statements. As at February 28, 2019 the
Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the
financial statements.
Use of Estimates and Assumptions
Preparation of the financial statements in conformity with generally
accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the period. Accordingly, actual results could differ from those estimates.
Cash and Cash Equivalents
For purposes of the statement of cash flows, the Company considers
highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.
Revenue Recognition
The Company recognizes revenue in accordance with ASC topic 605
“Revenue Recognition, and other applicable revenue recognition guidance under US GAAP. Sales revenue is recognized
for our retail and wholesale customers when: (i) persuasive evidence of a sales arrangement exists, (ii) the sales terms are fixed
or determinable, (iii) title and risk of loss have transferred, and (iv) collectability is reasonably assured — generally
when products are shipped to the customer and services are rendered, except in situations in which title passes upon receipt of
the products by the customer. Revenue consists of revenue earned for the sale of organic coconut water and services provided
by the Company. Revenue is recognized at the time the product is shipped to the customer and or services provided by the Company
are fulfilled.
Financial Instruments
All significant financial assets, financial liabilities and equity
instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant
for making a reasonable assessment of future cash flows,
interest rate risk and credit risk. Where practical the fair values
of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent
to fair value has been disclosed.
Loss per Common Share
The basic earnings (loss) per share is calculated by dividing the
Company’s net income available to common shareholders by the weighted average number of common shares during the year. The
diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders
by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding
is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share
are the same as basic earnings (loss) per share due to the lack of dilutive items in the Company.
Income Taxes
The Company follows the liability method of accounting for income
taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax balances and tax loss
carry-forwards. Deferred tax assets and liabilities are measured using enacted or substantially enacted tax rates expected to apply
to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment or substantive
enactment.
CHINA WUYI MOUNTAIN, LTD
NOTES TO CONDENSED FINANCIAL STATEMENTS
February
28, 2019 (unaudited)
|
NOTE 2 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (continued)
Stock-based Compensation
The Company follows ASC 718-10, "Stock
Compensation", which addresses the accounting for transactions in which an entity exchanges its equity instruments for
goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment
transactions. ASC 718-10 is a revision to SFAS No. 123, "Accounting for Stock-Based Compensation," and supersedes
Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," and its
related implementation guidance. ASC 718-10 requires measurement of the cost of employee services received in exchange for an
award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental
compensation costs arising from subsequent modifications of awards after the grant date must be recognized. The Company has
not adopted a stock option plan and has not granted any stock options. As at February 28, 2019 the Company had not adopted a
stock option plan nor had it granted any stock options. Accordingly, no stock-based compensation has been recorded to
date.
Recent Accounting Pronouncements
The Company’s management has evaluated all the recently issued,
but not yet effective, accounting standards that have been issued or proposed by the FASB or other standards-setting bodies through
the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material
effect on the Company’s financial position and results of operations.
NOTE
3 – CAPITAL STOCK
The Company’s capitalization is 200,000,000 common shares
with a par value of $0.001 per share and 2,000,000 preferred shares with a par value of $0.001 per share. Total shares issued as
of February 28, 2019 are 85,600,000 common shares and no preferred shares have been issued.
On July 26, 2016 the Company issued 800,000,000 (pre-split-10,000,000)
common shares at $0.0000125 (pre-split $0.001) per share to the former sole director and President of the Company for cash proceeds
of $10,000.
During March 2017 the Company received $9,600 in private placements
for the purchase of 25,600,000 (pre-split -320,000 common shares of the Company’s stock at $0.000375 (pre-split $0.03) per
share.
On April 6, 2017 the directors of the Company amended the Company’s
Articles of Incorporation to increase the authorized capital structure of the Corporation to include two million (2,000,000) shares
of preferred stock, par value $0.001, and to retain the previously authorized two hundred million (200,000,000) shares of common
stock, par value ($0.001).
On April 10, 2017, the founding shareholder of the Company returned
760,000,000 (9,500,000 pre-split) restricted shares of common stock to treasury and the shares were subsequently cancelled by the
Company. The shares were returned to treasury for $0.000000013 per share for a total consideration of $10 to the shareholder. Post-split
our founding shareholder will have 40,000,000 shares of common stock of the Company.
On April 20, 2017, the directors of the Company approved a special
resolution to undertake a forward split of the common stock of the Company on a basis of 80 new common shares for 1 old common
share. All references in these financial statements to number of common shares, price per share and weighted average number of
shares outstanding prior to the 80:1 forward split have been adjusted to reflect the stock split on a retroactive basis, unless
otherwise noted.
On May 2, 2018, the Company
entered into a subscription agreement with a China-based company, Grand Biotechnology Group Liaoning, (the authorized signor for
Grand Biotechnology is a 4.9% shareholder of the Company), for the issuance of an aggregate of 20,000,000 shares of restricted
common stock at $0.0075 per share for an aggregate purchase price of U.S.$150,000. On May 2, 2018, the Company issued 20,000,000
shares of restricted common stock. On May 15, 2018 the Company had received $100,000. As of February 28, 2019, $50,00 unpaid stock
purchased amount are recorded as “
Subscription receivable
“
under stockholders’ equity on the balance sheet.
CHINA WUYI MOUNTAIN, LTD
NOTES TO CONDENSED FINANCIAL STATEMENTS
February
28, 2019 (unaudited)
|
NOTE
3 – CAPITAL STOCK (continued)
As of February 28, 2019, the Company has not granted any stock options
and has not recorded any stock-based compensation.
As of February 28, 2019, the Company issued 0 shares of preferred
stock and 85,600,000 common shares are issued and outstanding.
NOTE
4 – OTHER RECEIVABLE
On December 12, 2018 the Company advanced $20,000 to China Dahongpao Hong Kong Co. Ltd. For legal work and
due diligence investigation on a potential merger/consolidation. If the potential merger/consolidation is abandoned by China Dahongpao
Hong Kong Co. Ltd., the funds will be payable within one year.
NOTE
5 – RELATED PARTY TRANSACTIONS
On October 19, 2017, the former CEO of the Company forgave all related
party loans to the Company in a total of $5,501. This will be reflected an increase in Additional-Paid-In-Capital in the financial
statements.
During the period ended August 31, 2018, Century Acquisition (Formerly
WP Acquisition Company, LLC), a 25.12% shareholder, advanced the Company $31,000 and paid invoices in the amount of $3,500 on behalf
of the Company. On June 8, 2018 the Company repaid a total of $10,000 to related party advances. During the period ended February
28, 2019 Century Acquisitions advance $6,000 and paid outstand invoice for $1,749. The amounts due to the related party are unsecured
and non- interest-bearing with no set terms of repayment.
As of February 28, 2019 the balance of due
to related party is $32,249 (August 31, 2018 - $24,500). The amounts due to the related party are unsecured and non- interest-bearing
with no set terms of repayment.
NOTE
6 – SUBSEQUENT EVENTS
On March 7, 2019 Century Acquisitions loaned to the Company $12,000.
The amount due to the related party are unsecured and non-interest bearing with no set terms of repayment.
Item 2. Management’s Discussion and Analysis of
Financial Condition and Results of Operations.
This section of this Form 10-Q includes a number
of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking
statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or
words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements.
These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially
from our predictions.
Results of Operations
For the three-month period ended February 28,
2019 and February 28, 2018 we had no revenues. Expenses for the three-month period ended February 28, 2019 totaled $17,198 resulting
in a net loss of $17,198. The net loss for the three-month period ended February 28, 2019 is a result of expenses of $17,198 comprised
primarily of; consulting expenses of $3,000; professional fees of $13,700; transfer agent expenses of $431; and bank service charges
of $67. Compared to the expenses for the three-months ended February 28, 2018 totaled $7,240 resulting in a net loss of $7,240.
The net loss for the three-month period ended February 28, 2018 is a result of expenses of $7,240 comprised primarily of; consulting
expenses of $3,000; professional fees of $3,500; transfer agent expenses of $297; office expenses of $353; and bank service charges
of $90; The increase in expenses for between the three-month periods February 28, 2019 and February 28, 2019 is due to the increase
in professional fees.
For the six-month period ended February 28,
2019 and February 28, 2018 we had no revenues. Expenses for the six-month period ended February 28, 2019 totaled $30,900 resulting
in a net loss of $30,900. The net loss for the six-month period ended February 28, 2019 is a result of expenses of $30,900 comprised
primarily of; consulting expenses of $16,403; professional fees of $13,700; transfer agent expenses of $728; and bank service charges
of $69. Compared to the expenses for the six-months ended February 28, 2018 totaled $10,003 resulting in a net loss of $7,503.
The net loss for the six-month period ended February 28, 2018 is a result of expenses of $10,003 and a net loss of $7,503 comprised
primarily of; consulting fees of $3,000; professional fees of $4,100; transfer agent expenses of $2,450; office expenses of $353;
and bank service charges of $100; and less $2,500 in other income The increase in expenses for between the six-month periods February
28, 2019 and February 28, 2018 is due to the increase in professional fees.
.
Capital Resources and Liquidity
We have generated no revenues to date and anticipate
until we generate a more rapid growth in revenues we will require additional financings in order to fully implement our plan of
operations. With the exception of cash advances from our sole Officer and Director, cash received in our initial offering and our
recent private placement of $150,000 (of which $100,000 had been received), we have not had any additional funding. We must raise
additional cash to implement our strategy and stay in business. Our president has verbally committed to continue to fund our operations.
However, this is not in writing and maybe rescinded at any time.
As of February 28, 2019, we had $1,106 in cash
and $32,249 due from a related party. As of August 31, 2018, we had $40,885 in cash, and $24,500 due to a related party. Total
liabilities as of February 28, 2019, were $39,548 compared to $28,427 in total liabilities at August 31, 2018. The funds available
to the Company will not be sufficient to fund the planned operations of the Company and maintain a reporting status. As of February
28, 2019, the Company owed $32,249 (August 31, 2018; $24,500) to a related party. All amounts due to the related party are unsecured,
non-interest bearing and have not set terms of repayment.
Company Operations
KOKOS GROUP INC. (now known as China WuYii
Mountain Ltd.) was incorporated in the State of Nevada as a for-profit Company on July 26, 2016 and established a fiscal year end
of August 31. The Company is organized to bottle, market, distribute and sell our own brand of coconut water, presently called
“Koos Coconut Water”. On November 10, 2017 the Board of directors and the majority of its shareholders of Kokos Group
Inc., amended the Company’s current Certificate of Incorporation in conformity with the applicable laws of the State of Nevada
to change the name of the Company from Kokos Group Inc. to CHINA WUYI MOUNTAIN, LTD. The Corporate action and the Amended Articles
became effective on May 26, 2018, following compliance with notification of FINRA.
On October 19, 2017
Mr. Lei Wang became its Chief Executive Officer, Chief Financial Officer and sole Director and Mr. Richard Rappaprt was appointed
Secretary. In addition Mr. Baterina and Messrs. Flemming H.H. Hansen and Arthur T. Claravall submitted his resignations from all
executive officer positions with the Company, including Chief Executive Officer and President effective October 19, 2017, and each
submitted their resignation as a member of the Board. On January 18, 2018, Richard Rappaport submitted his resignation as Secretary
of Kokos Group Inc. (the "Company"), effective immediately. On the same day, Ying Zhang was appointed
Secretary, effective immediately.
On February 25, 2017 the Company entered into
a Purchase Agreement to supply 69,300 private label Tetra Prisma 330ml packs of organic coconut water. The total purchase price
is $55,410. The purchaser has made the initial non-refundable payment of $2,500. Other items on payment schedule include; an additional
$2,500 non-refundable payment upon approval of private label artwork; $35,000 upon final order by purchaser; and $15,410 due on
delivery and acceptance of product by purchaser. Product will be delivered to purchaser within 90 days of the Company receiving
payments as per above schedule. On November 30, 2017 the client who entered into the Purchase Agreement has decided not to proceed
with the purchase order. The new management agreed to the cancellation of the Agreement.
Capital Stock
The Company’s capitalization is 200,000,000 common shares
with a par value of $0.001 per share and 2,000,000 preferred shares with a par value of $0.001 per share. Total shares issued as
of February 28, 2019 are 85,600,000 common shares and no preferred shares have been issued.
On July 26, 2016 the Company issued 800,000,000 (pre-split-10,000,000)
common shares at $0.0000125 (pre-split $0.001) per share to the former sole director and President of the Company for cash proceeds
of $10,000.
During March 2017 the Company received $9,600 in private placements
for the purchase of 25,600,000 (pre-split -320,000 common shares of the Company’s stock at $0.000375 (pre-split $0.03) per
share.
On April 6, 2017 the directors of the Company amended the Company’s
Articles of Incorporation to increase the authorized capital structure of the Corporation to include two million (2,000,000) shares
of preferred stock, par value $0.001, and to retain the previously authorized two hundred million (200,000,000) shares of common
stock, par value ($0.001).
On April 10, 2017, the founding shareholder of the Company returned
760,000,000 (9,500,000 pre-split) restricted shares of common stock to treasury and the shares were subsequently cancelled by the
Company. The shares were returned to treasury for $0.000000013 per share for a total consideration of $10 to the shareholder. Post-split
our founding shareholder will have 40,000,000 shares of common stock of the Company.
On April 20, 2017, the directors of the Company approved a special
resolution to undertake a forward split of the common stock of the Company on a basis of 80 new common shares for 1 old common
share. All references in these financial statements to number of common shares, price per share and weighted average number of
shares outstanding prior to the 80:1 forward split have been adjusted to reflect the stock split on a retroactive basis, unless
otherwise noted.
On May 2, 2018, the Company
entered into a subscription agreement with a China-based company, Grand Biotechnology Group Liaoning, (the authorized signor for
Grand Biotechnology is a 4.9% shareholder of the Company), for the issuance of an aggregate of 20,000,000 shares of restricted
common stock at $0.0075 per share for an aggregate purchase price of U.S.$150,000. On May 2, 2018, the Company issued 20,000,000
shares of restricted common stock. On May 15, 2018 the Company had received $100,000. As of February 28, 2019, $50,00 unpaid stock
purchased amount are recorded as “
Subscription receivable
“
under stockholders’ equity on the balance sheets.
As of February 28, 2019, the Company has not granted any stock options
and has not recorded any stock-based compensation.
As of February 28, 2019, the Company issued 0 shares of preferred
stock and 85,600,000 common shares are issued and outstanding.
Off-balance sheet arrangements
Other than the situation described in the section
titled Capital Recourses and Liquidity, the company has no off-balance sheet arrangements that have or are reasonably likely to
have a current or future effect or change on the company’s financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement”
generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the company
is a party, under which the company has (i) any obligation arising under a guarantee contract, derivative instrument or variable
interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as
credit, liquidity or market risk support for such assets
Item 3. Quantitative and Qualitative Disclosures About
Market Risk.
We are a smaller reporting company as defined by Rule 12b-2 of the
Exchange Act and are not required to provide the information required under this item.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
Disclosure controls and procedures are controls
and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under
the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC's
rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that
information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated
and communicated to management including our principal executive officer and principal financial officer as appropriate, to allow
timely decisions regarding required disclosure.
In connection with this quarterly report, as
required by Rule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the
design and operation of our company's disclosure controls and procedures. The material weaknesses in our disclosure control procedures
are as follows:
1
.
Lack
of formal policies and procedures necessary to adequately review significant accounting transactions.
We utilize
a third party independent contractor for the preparation of our financial statements. Although the financial statements and footnotes
are reviewed by our management, we do not have a formal policy to review significant accounting transactions and the accounting
treatment of such transactions. The third party independent contractor is not involved in our day to day operations and may not
be provided information from our management on a timely basis to allow for adequate reporting/consideration of certain transactions.
Based upon that evaluation, our company’s principal executive officer and principal financial officer concluded that as of
February 28, 2019 our disclosure controls and procedures were not effective due to the existence of material weaknesses in our
internal controls over financial reporting.
2
.
Audit
Committee and Financial Expert
. We do not have an audit committee with a financial expert and, thus, we lack the appropriate
oversight within the financial reporting process.
We intend to initiate measures to remediate
the identified material weaknesses, including, but not necessarily limited to, the following:
|
|
|
|
•
|
Establishing a formal review process of significant accounting transactions that includes participation of our principal executive officer, principal financial officer and corporate legal counsel.
|
|
|
|
|
•
|
Form an audit committee that will establish policies and procedures that will provide our Board of Directors with a formal review process that will among other things, assure that management controls and procedures are in place and being maintained consistently.
|
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control
over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) during the quarter ended February 28, 2019 that have materially
affected, or are reasonably likely to materially affect, our internal controls over financial reporting.